Can testosterone replacement therapy cause deep vein thrombosis (DVT)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Testosterone Replacement Therapy and Deep Vein Thrombosis Risk

Testosterone replacement therapy (TRT) can cause deep vein thrombosis, particularly within the first 6 months of treatment initiation, though the absolute risk increase is modest and the evidence remains mixed.

The Mechanism of Risk: Erythrocytosis

The primary pathway through which TRT may increase DVT risk is through erythrocytosis (elevated red blood cell count), which increases blood viscosity and theoretically promotes thrombosis 1. This risk varies significantly by formulation:

  • Intramuscular injections: 43.8% develop elevated hematocrit (>52%) 1
  • Transdermal gel (high dose): 17.9% develop erythrocytosis 1
  • Transdermal patches: 2.8-15.4% develop erythrocytosis 1

The FDA drug label for testosterone cypionate specifically requires monitoring hemoglobin and hematocrit levels to detect polycythemia in patients receiving long-term therapy 2.

What the Evidence Actually Shows

Guideline Perspective (2004)

The New England Journal of Medicine guideline noted that despite the theoretical risk from erythrocytosis, "no testosterone-associated thromboembolic events have been reported to date" as of 2004 1. However, they acknowledged that increased blood viscosity "could aggravate vascular disease" particularly in elderly patients 1.

Recent Research Evidence (Mixed Findings)

Studies showing increased risk:

  • A 2016 UK population-based case-control study found the adjusted rate ratio for VTE was 1.63 during the first 6 months of TRT (95% CI: 1.12-2.37), corresponding to 10 additional VTE cases per 10,000 person-years above baseline 3
  • After 6 months, the risk normalized (rate ratio 1.00) 3
  • A 2020 case-crossover study found testosterone therapy associated with increased short-term VTE risk in both men with hypogonadism (OR 2.32) and without (OR 2.02), with higher risk in younger men 4

Studies showing no increased risk:

  • A 2024 meta-analysis of RCTs found TRT did not influence VTE risk (OR 1.42,95% CI: 0.22-9.03, p=0.71) 5
  • A 2021 meta-analysis of 13 RCTs (n=5,050) found no association with VTE (RR 1.03,95% CI: 0.49-2.14) 6
  • A 2016 Veterans Affairs retrospective cohort (71,407 subjects) detected no significant association between TRT and DVT/PE 7
  • A 2020 American College of Physicians guideline review found testosterone was not associated with increased risk for pulmonary embolism or DVT in observational studies 8

Clinical Algorithm for Risk Assessment

High-Risk Scenarios (Exercise Caution):

  1. First 6 months of treatment - highest risk period 3
  2. Intramuscular formulations - greatest erythrocytosis risk 1
  3. Patients with baseline risk factors: COPD, pre-existing polycythemia, elderly with vascular disease 1
  4. Younger men without true hypogonadism - potentially higher relative risk 4

Monitoring Strategy:

  • Baseline: Hematocrit/hemoglobin before starting TRT 2
  • During treatment: Check hematocrit at 3 months (when most erythrocytosis develops) 1, then periodically
  • If hematocrit >52%: Consider dose reduction, withholding testosterone, therapeutic phlebotomy, or blood donation 1

Critical Caveats

The evidence contradiction exists because:

  • RCTs are underpowered for rare thrombotic events 8, 6
  • Observational studies suffer from confounding by indication (sicker patients may avoid TRT) 8
  • Most trials exclude high-risk patients (recent cardiovascular events, elevated PSA) 8
  • Follow-up duration in trials is typically <1 year 8

The absolute risk remains low even in positive studies: approximately 1 additional VTE per 1,000 patients treated for 6 months 3.

Practical Recommendation

For patients considering TRT: The risk of DVT exists but is modest and time-limited. Prioritize transdermal formulations over injections to minimize erythrocytosis risk 1. Monitor hematocrit closely in the first 6 months 3. In patients with pre-existing VTE risk factors (obesity, immobility, thrombophilia, COPD), the theoretical risk from increased blood viscosity warrants heightened surveillance 1, 2. The decision should weigh this modest DVT risk against the patient's symptoms and quality of life impairment from hypogonadism.

References

Related Questions

Is testosterone replacement therapy appropriate for a patient with a prior history of venous or arterial thrombosis?
Does testosterone replacement therapy increase the risk of pulmonary embolism?
In a 67-year-old man, does testosterone replacement therapy increase the risk of prostate cancer or venous thromboembolism?
What are the perioperative recommendations for a patient receiving testosterone injections who is scheduled for right shoulder arthroscopy?
In a mechanically ventilated patient who cannot receive estrogen due to contraindication (e.g., upper‑extremity deep vein thrombosis), how can progesterone be administered since there is no approved intravenous formulation?
In a patient with bipolar disorder who has memory impairment, racing thoughts, and mood swings while on lamotrigine 200 mg daily and quetiapine 50 mg at bedtime, what psychiatric management steps should be taken?
If I had a prolonged ischemic priapism that partially resolved but left the penis hard‑flaccid, will I have no erectile function one month later?
What is the appropriate evaluation and management for a patient with an adrenal mass, hyponatremia, and findings on chest CT?
What is the best psychotropic management for a 63-year-old male nursing home resident with alcohol-induced dementia who is currently taking risperidone 0.5 mg twice daily and trazodone 25 mg at bedtime, and who continues to have dementia-related psychosis, wandering, hostile aggression, and insomnia?
For a bipolar disorder patient on lamotrigine 200 mg daily and quetiapine 50 mg at bedtime who is experiencing memory problems while awaiting a neurology consult, can the quetiapine dose be increased?
Is it appropriate to start lithium in a patient with unexplained cognitive impairment and memory problems who is currently taking lamotrigine 200 mg daily?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.